Boston Scientific Corporation (FRA:BSX)

Germany flag Germany · Delayed Price · Currency is EUR
90.40
+1.40 (1.57%)
Jun 6, 2025, 6:11 PM CET
29.14%
Market Cap 132.63B
Revenue (ttm) 16.24B
Net Income (ttm) 1.88B
Shares Out n/a
EPS (ttm) 1.27
PE Ratio 70.55
Forward PE 34.37
Dividend n/a
Ex-Dividend Date n/a
Volume 2
Average Volume 399
Open 90.00
Previous Close 89.00
Day's Range 90.00 - 90.40
52-Week Range 65.50 - 104.00
Beta n/a
RSI 45.16
Earnings Date Jul 23, 2025

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1979
Employees 53,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BSX
Full Company Profile

Financial Performance

In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.

Financial numbers in USD Financial Statements

News

Is Boston Scientific Gaining or Losing Market Support?

Boston Scientific's (NYSE: BSX) short percent of float has risen 6.6% since its last report. The company recently reported that it has 16.75 million shares sold short , which is 1.13% of all regular ...

2 days ago - Benzinga

P/E Ratio Insights for Boston Scientific

In the current market session, Boston Scientific Inc. (NYSE: BSX) stock price is at $104.20, after a 0.29% drop. However, over the past month, the company's stock increased by 0.10% , and in the past...

7 days ago - Benzinga

Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire

Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.

9 days ago - Investor's Business Daily

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Boston Scientific Corporation (NYSE: BSX) is pulling the plug on its ACURATE neo2 and Prime aortic valve systems . What Happened : The medical technology giant halted global sales and abandoned regul...

9 days ago - Benzinga

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.

9 days ago - Benzinga

How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.

9 days ago - Investor's Business Daily

Boston Scientific to not seek US approval for heart device amid regulatory challenges

Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

10 days ago - Reuters

$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today

Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.95% on an annualized basis producing an average annual return of 21.03%. Currently, Boston Scientific has a marke...

17 days ago - Benzinga

Boston Scientific Stock Flirts With A Buy Point, Once Again

Boston Scientific stock is wavering around the buy point of a double-bottom base. The company recently raised its 2025 earnings outlook.

4 weeks ago - Investor's Business Daily

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today

Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a marke...

5 weeks ago - Benzinga

Boston Scientific announces upcoming investor conference schedule

MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

5 weeks ago - PRNewsWire

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

5 weeks ago - Seeking Alpha

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints

Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

6 weeks ago - PRNewsWire

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

Boston Scientific Corporation (NYSE: BSX) posted better-than-expected earnings for the first quarter on Wednesday . The company reported first-quarter 2025 revenues of $4.66 billion, beating the cons...

6 weeks ago - Benzinga

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.

6 weeks ago - Benzinga

IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries

Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.

6 weeks ago - Investor's Business Daily

Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ETCompany ParticipantsJon Monson - Senior Vice President,...

6 weeks ago - Seeking Alpha

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition

Boston Scientific Corporation (NYSE: BSX) on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion . Sales increased 20.9% on a reported bas...

6 weeks ago - Benzinga

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition

Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.

6 weeks ago - Benzinga

Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire

Shares of Boston Scientific rose sharply Wednesday after the firm posted better-than-expected quarterly results.

6 weeks ago - Investopedia